GSA Capital Partners LLP Buys New Position in Alphatec Holdings, Inc. (NASDAQ:ATEC)

GSA Capital Partners LLP purchased a new position in Alphatec Holdings, Inc. (NASDAQ:ATEC) in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 77,577 shares of the medical technology company’s stock, valued at approximately $431,000. GSA Capital Partners LLP owned 0.05% of Alphatec at the end of the most recent reporting period.

Several other hedge funds have also recently modified their holdings of ATEC. ProShare Advisors LLC grew its holdings in shares of Alphatec by 8.5% in the first quarter. ProShare Advisors LLC now owns 16,572 shares of the medical technology company’s stock worth $229,000 after purchasing an additional 1,304 shares during the last quarter. Vanguard Group Inc. raised its holdings in shares of Alphatec by 1.2% during the 1st quarter. Vanguard Group Inc. now owns 5,458,847 shares of the medical technology company’s stock worth $75,278,000 after acquiring an additional 64,648 shares during the period. EntryPoint Capital LLC purchased a new position in shares of Alphatec during the 1st quarter worth $141,000. Price T Rowe Associates Inc. MD raised its holdings in Alphatec by 14.2% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 26,346 shares of the medical technology company’s stock valued at $364,000 after buying an additional 3,268 shares during the period. Finally, Bayesian Capital Management LP raised its holdings in Alphatec by 5.6% in the 1st quarter. Bayesian Capital Management LP now owns 27,000 shares of the medical technology company’s stock valued at $372,000 after buying an additional 1,442 shares during the period. Hedge funds and other institutional investors own 66.35% of the company’s stock.

Alphatec Stock Performance

ATEC stock opened at $9.93 on Thursday. The business’s 50-day moving average price is $6.52 and its two-hundred day moving average price is $8.28. The company has a current ratio of 2.32, a quick ratio of 1.15 and a debt-to-equity ratio of 30.21. The firm has a market cap of $1.41 billion, a PE ratio of -7.76 and a beta of 1.31. Alphatec Holdings, Inc. has a 1-year low of $4.88 and a 1-year high of $17.34.

Analyst Ratings Changes

ATEC has been the subject of a number of analyst reports. Barclays boosted their price objective on Alphatec from $19.00 to $20.00 and gave the stock an “overweight” rating in a research report on Tuesday. Canaccord Genuity Group reaffirmed a “buy” rating and set a $20.00 price objective on shares of Alphatec in a research note on Friday, August 30th. Wells Fargo & Company reduced their target price on Alphatec from $26.00 to $19.00 and set an “overweight” rating on the stock in a research report on Thursday, August 1st. Needham & Company LLC restated a “buy” rating and issued a $13.00 price objective on shares of Alphatec in a report on Thursday, October 31st. Finally, Morgan Stanley downgraded Alphatec from an “overweight” rating to an “equal weight” rating in a report on Thursday, August 1st. One equities research analyst has rated the stock with a hold rating and eight have assigned a buy rating to the company. Based on data from MarketBeat.com, Alphatec currently has an average rating of “Moderate Buy” and a consensus target price of $17.11.

About Alphatec

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.